Statistics for Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)
Total visits
| views | |
|---|---|
| Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508) | 225 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| nihms664575.pdf | 203 |
| java.util.UUID:d01428ea-0320-4af8-8f6a-2da6212bb18a | 44 |
| java.util.UUID:3988f734-b858-4c37-b0a7-f2674448b844 | 10 |
| java.util.UUID:b48a0be6-b008-4fbe-a357-84616535b70a | 6 |
Top country views
| views | |
|---|---|
| United States | 155 |
| Germany | 16 |
| Sweden | 8 |
| Ukraine | 7 |
| Italy | 5 |
| Russia | 5 |
| Canada | 2 |
| China | 2 |
| France | 1 |
| United Kingdom | 1 |
| Lebanon | 1 |
| Malaysia | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 52 |
| Fairfield | 21 |
| Ann Arbor | 18 |
| Kiez | 15 |
| Houston | 11 |
| White Plains | 9 |
| Jacksonville | 7 |
| Kiev | 7 |
| Stockholm | 6 |
| Cambridge | 5 |
| Genova | 4 |
| Saint Petersburg | 3 |
| Beijing | 2 |
| San Francisco | 2 |
| Toronto | 2 |
| Baltimore | 1 |
| Beirut | 1 |
| Grùmolo | 1 |
| Gunzenhausen | 1 |
| Kalmar | 1 |
| Kista | 1 |
| Lake Mary | 1 |
| Moscow | 1 |
| Norwalk | 1 |
| Philadelphia | 1 |
| Roubaix | 1 |
| Scottsdale | 1 |
| Seremban | 1 |
| Tula | 1 |
| Washington | 1 |